艾曲泊帕、重组人血小板生成素联合标准免疫抑制治疗重型再生障碍性贫血16例疗效及安全性分析

OBJECTIVE: To evaluate the efficacy and safety of combination therapy of eltrombopag, recombinant human thrombopoietin (rhTPO), and standard immunosuppressive therapy (IST) for severe aplastic anemia (SAA). METHODS: A total of 16 cases with SAA treated with IST combined with eltrombopag and rhTPO were retrospectively analyzed. RESULTS: At 3 months, the total response rate was 81.3％, and the complete hematological response rate was 37.5％. At 6 months, the total response rate was 87.5％, and the complete hematological response rate was 50.0％. The median time of platelet transfusion independence was 35 (16–78) days, the median time of red blood cell transfusion independence was 47.5 (15–105) days, the median platelet transfusion was 5.5 (3–20) U, and the median red blood cell transfusion was 6.5 (2–16) U. CONCLUSION: The combination of eltrombopag and rhTPO can improve the hematological response rate of IST for SAA and the quality of hematological remission with minimal toxic effects.